Clinical trial
Lipid Efficacy/Tolerability Study (0524A-020)
NCT00269204 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00269204 |
|---|---|
| Title | Lipid Efficacy/Tolerability Study (0524A-020) |
| Official title | A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Hypercholesterolaemia, Mixed Hyperlipidaemia |
| Intervention type | Drug |
| Interventions | niacin (+) laropiprant, ER-niacin |
| Enrollment | 1,620 |
| Start date | Dec 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Dec 23, 2005 |
| Last update posted | Jul 27, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: